Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
13.05
-0.03 (-0.23%)
Jun 29, 2026, 10:18 AM EDT - Market open
Climb Bio Employees
As of December 31, 2025, Climb Bio had 29 total employees, including 28 full-time and 1 part-time employees. The number of employees increased by 11 or 61.11% compared to the previous year.
Employees
29
Change (1Y)
11
Growth (1Y)
61.11%
Revenue / Employee
n/a
Profits / Employee
-$1,820,414
Market Cap
747.25M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29 | 11 | 61.11% |
| Dec 31, 2024 | 18 | 7 | 63.64% |
| Dec 31, 2023 | 11 | -32 | -74.42% |
| Dec 31, 2022 | 43 | 12 | 38.71% |
| Dec 31, 2021 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Rigel Pharmaceuticals | 174 |
| Allogene Therapeutics | 152 |
| Aura Biosciences | 113 |
| Inventiva | 77 |
| CytomX Therapeutics | 69 |
| SpyGlass Pharma | 68 |
| Zevra Therapeutics | 61 |
| Oculis Holding AG | 60 |
CLYM News
- 17 days ago - Climb Bio price target raised to $20 from $19 at BTIG - TheFly
- 18 days ago - Climb Bio announces initial data from budoprutug study at EHA - TheFly
- 18 days ago - Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 - GlobeNewsWire
- 21 days ago - Climb Bio initiated with a Buy at Guggenheim - TheFly
- 24 days ago - Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development - GlobeNewsWire
- 24 days ago - Climb Bio Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Climb Bio registers to sell 11.59M shares of common stock for holders - TheFly
- 4 weeks ago - Climb Bio Registration statement: Registration filing - Filings